Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non-small-cell lung cancer.

t platinum-based therapy (HR: 0.52; 95%CI: 0.28–0.96); it was also superior to the combination of ramucirumab and doublet platinum-based therapy (HR: 0.58; 95%CI: 0.32–1.05) and the combination of bevacizumab and doublet platinum-based therapy (HR: 0.69; 95%CI: 0.45–1.07), although these difference did not reach statistical significance.

also in 111,027 other papers